
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
An opinion piece in the






